
Gregory H. Curran
Examiner (ID: 18871, Phone: (571)270-7505 , Office: P/2852 )
| Most Active Art Unit | 2852 |
| Art Unit(s) | 2852, 4175 |
| Total Applications | 1223 |
| Issued Applications | 1098 |
| Pending Applications | 64 |
| Abandoned Applications | 86 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20163905
[patent_doc_number] => 20250255951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => Vaccines against Chlamydia sp.
[patent_app_type] => utility
[patent_app_number] => 19/197254
[patent_app_country] => US
[patent_app_date] => 2025-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15021
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19197254
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/197254 | Vaccines against Chlamydia sp. | May 1, 2025 | Pending |
Array
(
[id] => 19984036
[patent_doc_number] => 20250122258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/889859
[patent_app_country] => US
[patent_app_date] => 2024-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10066
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/889859 | COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS | Sep 18, 2024 | Pending |
Array
(
[id] => 19984036
[patent_doc_number] => 20250122258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/889859
[patent_app_country] => US
[patent_app_date] => 2024-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10066
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18889859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/889859 | COMPOSITIONS AND USES OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ANTAGONISTS | Sep 18, 2024 | Pending |
Array
(
[id] => 19479419
[patent_doc_number] => 20240327461
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => APELIN POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/497081
[patent_app_country] => US
[patent_app_date] => 2024-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497081 | APELIN POLYPEPTIDES | Jun 10, 2024 | Pending |
Array
(
[id] => 19479419
[patent_doc_number] => 20240327461
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => APELIN POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/497081
[patent_app_country] => US
[patent_app_date] => 2024-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497081 | APELIN POLYPEPTIDES | Jun 10, 2024 | Pending |
Array
(
[id] => 19990915
[patent_doc_number] => 20250129137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => CD71 BINDING FIBRONECTIN TYPE III DOMAINS
[patent_app_type] => utility
[patent_app_number] => 18/675958
[patent_app_country] => US
[patent_app_date] => 2024-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18675958
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/675958 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | May 27, 2024 | Pending |
Array
(
[id] => 19417379
[patent_doc_number] => 20240293502
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN
[patent_app_type] => utility
[patent_app_number] => 18/654900
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654900
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/654900 | PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN | May 2, 2024 | Pending |
Array
(
[id] => 19417379
[patent_doc_number] => 20240293502
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN
[patent_app_type] => utility
[patent_app_number] => 18/654900
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654900
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/654900 | PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN | May 2, 2024 | Pending |
Array
(
[id] => 19403642
[patent_doc_number] => 20240287153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => Treating Inflammatory Lung Disease
[patent_app_type] => utility
[patent_app_number] => 18/639779
[patent_app_country] => US
[patent_app_date] => 2024-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20007
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18639779
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/639779 | Treating Inflammatory Lung Disease | Apr 17, 2024 | Pending |
Array
(
[id] => 19379430
[patent_doc_number] => 20240269300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/603127
[patent_app_country] => US
[patent_app_date] => 2024-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33575
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603127
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603127 | METHODS OF USING GLYCOPOLYSIALYLATED THERAPEUTIC PROTEINS | Mar 11, 2024 | Pending |
Array
(
[id] => 19380944
[patent_doc_number] => 20240270814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => T CELL RECEPTORS RECOGNIZING MUTATED P53
[patent_app_type] => utility
[patent_app_number] => 18/583139
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43976
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 425
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583139
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/583139 | T CELL RECEPTORS RECOGNIZING MUTATED P53 | Feb 20, 2024 | Pending |
Array
(
[id] => 19910272
[patent_doc_number] => 12286468
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-29
[patent_title] => Scaffold proteins
[patent_app_type] => utility
[patent_app_number] => 18/436355
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 78
[patent_figures_cnt] => 21
[patent_no_of_words] => 67027
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436355
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436355 | Scaffold proteins | Feb 7, 2024 | Issued |
Array
(
[id] => 19186355
[patent_doc_number] => 20240165268
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A
[patent_app_type] => utility
[patent_app_number] => 18/420397
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31784
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420397
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420397 | TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A | Jan 22, 2024 | Abandoned |
Array
(
[id] => 19265358
[patent_doc_number] => 20240209057
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => NOVEL PTH MIMETIC PEPTIDE BASED ON PROTEIN DOMAIN RECONSTRUCTION AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/412585
[patent_app_country] => US
[patent_app_date] => 2024-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18412585
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/412585 | PTH mimetic peptide based on protein domain reconstruction and application thereof | Jan 13, 2024 | Issued |
Array
(
[id] => 19111093
[patent_doc_number] => 20240122843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => METHODS OF SCAR PREVENTION AND/OR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/393925
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20526
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393925
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/393925 | METHODS OF SCAR PREVENTION AND/OR TREATMENT | Dec 21, 2023 | Abandoned |
Array
(
[id] => 19111093
[patent_doc_number] => 20240122843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => METHODS OF SCAR PREVENTION AND/OR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/393925
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20526
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393925
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/393925 | METHODS OF SCAR PREVENTION AND/OR TREATMENT | Dec 21, 2023 | Abandoned |
Array
(
[id] => 19096438
[patent_doc_number] => 20240115665
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/543196
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543196
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/543196 | USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | Dec 17, 2023 | Pending |
Array
(
[id] => 19096438
[patent_doc_number] => 20240115665
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/543196
[patent_app_country] => US
[patent_app_date] => 2023-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543196
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/543196 | USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | Dec 17, 2023 | Pending |
Array
(
[id] => 19345200
[patent_doc_number] => 20240254163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/515100
[patent_app_country] => US
[patent_app_date] => 2023-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34912
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515100
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515100 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Nov 19, 2023 | Pending |
Array
(
[id] => 19345200
[patent_doc_number] => 20240254163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/515100
[patent_app_country] => US
[patent_app_date] => 2023-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34912
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515100
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515100 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | Nov 19, 2023 | Pending |